Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israeli Chief of Staff declares new border with Gaza Strip - 2Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- 3Red Sea arena: Yemen’s Houthis open fourth front in Iran war, with global implications
- 410 Demonstrated Systems to Develop Your Internet based Business
- 56 Popular Ladies' Aromas On the planet
- New Jordan security fence could be done in early 2028
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- 5 Breakout Stars in Ongoing television Series
- Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland
- Embrace Effortlessness: Moderation and Cleaning up Tips
- Looking for under-the-radar adventures? Try Norway's Vesterålen
- The Delight of Perusing: Book Proposals for Each Class
- Novo and Lilly cut prices of weight-loss drugs in China
- Teen drug use remains low, but survey finds small rise in heroin and cocaine use
